Social media gurus Gwee and Monseau move on to new jobs

Share this article:
Shwen Gwee
Shwen Gwee
Two of the drug industry's top social media experts, Shwen Gwee and Marc Monseau, are changing jobs.

Shwen Gwee is leaving Vertex to co-lead Edelman's digital health practice.

Gwee, one of the drug industry's top digital and social media gurus, will work out of Edelman's New York office and report to Bruce Hayes, general manager of Edelman's New York healthcare practice, where he'll join former AstraZeneca marketer Gigi Peterkin. Gwee was digital strategy and social media lead at Vertex for several years and also co-founded the Social Health Unconference and the SocialPharmer Network. He's also a member of MM&M's editorial advisory board.

Gwee said on his Med2.0 blog: “While I was able to roll out some cool and interesting digital initiatives during my time at Vertex, my new role at Edelman will allow me to serve the industry in a greater capacity and spread my wings more broadly by challenging me to think across multiple audiences, diseases, and brands/clients.”

Monseau, who has been with J&J for 14 years, including three as director of corporate communication and social media, is leaving the company to open up his own firm, MDM Communications, which "will provide social and digital communication support focusing on healthcare and related industries to help companies become more involved in the social web," he told MM&M.

Gwee and Monseau will hold a live discussion entitled “We've got your social media guidelines right here” at the inaugural MM&M Virtual Summit on May 24. To register for free, click here.
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.